Glenmark Pharmaceutical, a Mumbai-based drug firm declared On Saturday, that it had launched its first oral antiviral drug for the treatment of patients with mild to moderate coronavirus. The drug is named Favipiravir and is launched under the brand name FabiFlu. The Active Pharmaceutical Ingredients (API) of the medicine are produced at the company’s Ankleshwar plant while its formulation being manufactured at its Baddi facility in Himachal Pradesh.
As said by the Glenmark Pharmaceuticals, this medicine will be available as a 200mg tablet at an MRP (Maximum retail price) of Rs 3,500 per strip that will consist of 34 tablets, which means that it will cost Rs 103 per tablet. The dosage recommended for the drug is 1800mg twice on day one, then followed by 800mg twice regularly up to the 14th day.
This medicine can be given to diabetes and heart disease patients too with mild to moderate COVID symptoms. It had shown a rapid reduction in viral load within a period of four days and provides quite a faster symptomatic and radiological improvement of about 88%. “We chose to initiate work on Favipiravir, as it has proven in-vitro activity against SARS CoV2 virus, which is the virus responsible for Covid-19. Second is, it has a wide therapeutic safety margin for COVID-19 at the dose that we administer”, said Sujesh Vasudevan, Glenmark Pharmaceuticals President, India Formulations, Middle East, and Africa.
- Panacea Biotec ties up with US-based Refana Inc for COVID-19 vaccine
- Is it Time to Introduce Homeopathy and Alternative Medicines to Fight against Covid-19?
The medicine will be available both in hospitals as well as through retail channels, “Glenmark will work closely with the government and medical community to make FabiFlu quickly accessible to patients across the country”, said the chairman and managing director of Glenmark Pharmaceuticals, Glenn Saldanha. But the availability of the drug will be restricted. Until and unless the patients will be able to provide signed informed consent (or prescription), the medicine will not be provided to them, added Glenmark.
Having received the manufacturing and marketing approval from the Drugs Controller General of India (DCGI) on Friday, the company now expects and hopes that amidst the existing pressure, with the increasing number of affected and deaths per day, the introduction of such an effective medicine like FabiFlu will help in tackling the health crisis in India by offering them a timely and much-needed therapy option.
Glenmark claimed that it will be able to provide the medicine for around 82,500 patients, considering two stripes per patient, in the first month itself. Their primary concern is to stabilize their focus holistically on the manufacturing and marketing of the drug so that it becomes easily available for the patients in need throughout the entire country. It will also make proper arrangements so that it can support the public and private healthcare centres in time and as per their need.
With the launch of FabiFlu, Glenmark Pharmaceuticals, today, have experienced a surge of 35%. The scrip jumped 34.99% to Rs 552.25, which is a 52-week rise, on the BSE, marking its hugest rise in history within a day.